This study not only establishes CoQ-FSP1 as a new downstream effector of the KEAP1-NRF2 pathway but also provides an additional therapeutic target for treating KEAP1-mutant lung cancer 57. The gene discussed is NFE2L2; the disease is lung carcinoma.